L'un des principaux objectifs de Life4me + - est de prévenir de nouveaux cas de VIH et d'autres IST, d'hépatite C et de tuberculose.

L'application aide à établir une communication anonyme entre les médecins et les personnes séropositives. Elle vous permet d'organiser facilement votre horaire de prise de médicaments et de définir des rappels cachés et personnalisés.

Arrière
10 janvier 2020, 14:28
2504

New drug, Fostemsavir, to treat those with multi-drug resistant HIV

New drug, Fostemsavir, to treat those with multi-drug resistant HIV - photo 1

Fostemsavir, an innovative new approach to HIV treatment that could help treatment experienced people everywhere, is to go authorisation review at the European Medicines Agency (EMA).

On January 10th 2020 ViiV Healthcare announced the submission of a marketing authorisation application to the European Medicines Agency (EMA) seeking approval of fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV-1 infection. 

The application seeks approval of fostemsavir, used in combination with other antiretrovirals, for the treatment of adults with multi-drug resistance who have far fewer treatment options available due to resistance, intolerance or drug-drug interactions.

Fostemsavir is a the first in a new class of HIV treatments known as 'attachment inhibitors' that work by binding directly to the glycoprotein 120 (gp120) subunit on the surface of the virus. By binding to this location on the virus, fostemsavir blocks HIV from attaching to host immune system CD4+ T-cells and other immune cells, thereby preventing HIV from infecting those cells and multiplying.

Because of this unique mechanism of action, there is no demonstrated resistance to other classes of antiretrovirals, which may help patients who have become resistant to most other medicines. Fostemsavir is yet to receive regulatory authorisation for prescription to patients in any country.

The efficacy of fostemsavir in heavily treatment-experienced adults with HIV-1 infection is based on 96-week data from the phase III, partially-randomised, international, double-blind, placebo-controlled BRIGHTE study.

At Week 96, 60% of patients receiving fostemsavir plus an optimised background therapy in the randomised cohort (n=163/272) achieved virologic suppression (a viral load below 40 copies / mL) as well as a mean change from baseline of +205 CD4+ T-cells / mL.

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has granted an accelerated assessment for the fostemsavir authorisation. Accelerated assessment reduces the timeframe for review and is awarded if the CHMP determines the product is of major interest for public health and therapeutic innovation.

Auteur: Tom Hayes
Traducteur: Tom Hayes

Partager sur les réseaux sociaux